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Antimicrobial agentsAbstract Antibiotic resistance is a problem of deep scientiﬁc concern both in hospital and commu-
nity settings. Rapid detection in clinical laboratories is essential for the judicious recognition of
antimicrobial resistant organisms. Production of extended-spectrum b-lactamases (ESBLs) is a
signiﬁcant resistance-mechanism that impedes the antimicrobial treatment of infections caused by
Enterobacteriaceae and is a serious threat to the currently available antibiotic armory. ESBLs are
classiﬁed into several groups according to their amino acid sequence homology. Proper infection
control practices and barriers are essential to prevent spread and outbreaks of ESBL producing bac-
teria. As bacteria have developed different strategies to counter the effects of antibiotics, the iden-
tiﬁcation of the resistance mechanism may help in the discovery and design of new antimicrobial
agents. The carbapenems are widely regarded as the drugs of choice for the treatment of severe
infections caused by ESBL-producing Enterobacteriaceae, although comparative clinical trials are
scarce. Hence, more expeditious diagnostic testing of ESBL-producing bacteria and the feasible
modiﬁcation of guidelines for community-onset bacteremia associated with different infections
are prescribed.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Resistance of pathogenic organisms to countenance antibiotics
has become a worldwide problem with serious consequences
on the treatment of infectious diseases. The heightened use/
misuse of antibiotics in human medicine, agriculture and
veterinary is primarily contributing to the phenomenon. There
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cause either community infections or hospital acquired infec-
tions. Of particular interest are the multidrug resistant patho-
gens, e.g. Escherichia coli, Klebsiella pneumoniae, Acinetobacter
baumannii, methicillin-resistant Staphylococcus aureus, penicil-
lin-resistant Streptococcus pneumoniae, vancomycin-resistant
Enterococcus, and extensively drug-resistant Mycobacterium
tuberculosis (Alekshun and Levy, 2007).
Beta-lactam antimicrobial agents exhibit the most common
treatment for bacterial infections and continue to be the prom-
inent cause of resistance to b-lactam antibiotics among Gram-
negative bacteria worldwide. The persistent exposure of bacte-
rial strains to a multitude of b-lactams has induced dynamic
and continuous production and mutation of b-lactamases in
these bacteria, expanding their activity even against the newly
developed b-lactam antibiotics. These enzymes are known as
extended-spectrum b-lactamases (ESBLs) (Pitout and
Laupland, 2008; Paterson and Bonomo, 2005). Treatment of
these multiple drug resistant organisms is a deep scientiﬁc
concern. At the level of a wider geographic scale, the incidence
of ESBL-producing organisms is difﬁcult to resolve due to
various reasons, difﬁculty in detecting ESBL production and
inconsistencies in reporting (Steward et al., 2000). Recently,
a signiﬁcant increase in the incidents of ESBL-related
infections has been observed throughout the globe (Rupinder
et al., 2013; Abhijit et al., 2013; Majda et al., 2013; Meeta
et al., 2013; Kritu et al., 2013; Fatemeh et al., 2012; Gupta,
2007).2. How do antibiotics work?
There are ﬁve major modes of antibiotic mechanisms of activ-
ity and here are some examples.
2.1. Interference with cell wall synthesis
Beta-lactam antibiotics like penicillin and cephalosporin
impede enzymes that are responsible for the formation of pep-
tidoglycan layer (Benton et al., 2007).
2.2. Inhibition of protein synthesis
Oxazolidinones, the newest class of antibiotics, interact with
the A site of the bacterial ribosome where they should interfere
with the placement of the aminoacyl-tRNA. Tetracyclines
interfere with protein synthesis by binding to 30S subunit of
ribosome, thereby weakening the ribosome-tRNA interaction.
Macrolides bind to the 50S ribosomal subunit and inhibit the
elongation of nascent polypeptide chains. Chloramphenicol
binds to the 50S ribosomal subunit blocking peptidyl
transferase reaction. Aminoglycosides inhibit initiation of
protein synthesis and bind to the 30S ribosomal subunit
(Leach et al., 2007).
2.3. Interference with nucleic acid synthesis
Rifampicin interferes with a DNA-directed RNA polymerase.
Quinolones inhibit DNA synthesis with interference of type II
topoisomerase, DNA gyrase and type IV topoisomeraseduring replication cycle causing double strand break (Strohl,
1997).
2.4. Inhibition of a metabolic pathway
Sulfonamides (e.g. sulfamethoxazole) and trimethoprim each
block the key steps in the folate synthesis, which is a cofactor
in the biosynthesis of nucleotides, the building blocks of DNA
and RNA (Strohl, 1997).
2.5. Disorganizing of the cell membrane
The primary site of action is the cytoplasmic membrane of
Gram-positive bacteria, or the inner membrane of Gram-neg-
ative bacteria. It is hypothesized that polymyxins exert their
inhibitory effects by increasing bacterial membrane permeabil-
ity, causing leakage of bacterial content. The cyclic lipopeptide
daptomycin displays rapid bactericidal activity by binding to
the cytoplasmic membrane in a calcium-dependent manner
and oligomerizing in the membrane, leading to an efﬂux of
potassium from the bacterial cell and cell death (Straus and
Hancock, 2006). Antibiotic resistant versus antimicrobial
activity mechanism is shown in Fig. 1.
3. Antibiotic resistance mechanism
Antibiotic resistance is the reduction in effectiveness of a drug
such as an antimicrobial or an antineoplastic in curing a dis-
ease or condition. When the antibiotic is not intended to kill
or inhibit a pathogen, then the term is equivalent to dosage
failure or drug tolerance. More commonly, the term is used
in the context of resistance that pathogens have ‘‘acquired’’,
that is, resistance has evolved. When an organism is resistant
to more than one drug, it is said to be multidrug-resistant
(Fisher and Mobashery, 2010). Bacterial strains may possess
different types of resistant mechanisms which are shown in
Fig. 2 and are explained as follows.
3.1. Antibiotic inactivation
3.1.1. By hydrolysis
Many antibiotics have chemical bonds such as amides and
esters which are hydrolytically susceptible. Several enzymes
are known to ruin antibiotic activity by targeting and cleaving
these bonds. These enzymes can often be excreted. Extended-
spectrum b-lactamases (ESBLs) mediate resistance to all
penicillins, third generation cephalosporins (e.g. ceftazidime,
cefotaxime, and ceftriaxone) and aztreonam, but not to
cephamycins (cefoxitin and cefotetan) and carbapenems
(Bonnet, 2004).
3.1.2. By redox process
The pathogenic bacteria infrequently exploited oxidation or
reduction of antibiotics. However, there are a few examples
of this strategy (Yang et al., 2004). One is the oxidation of
tetracycline antibiotics by the TetX enzyme. Streptomyces
virginiae, a producer of the type A streptogramin antibiotic
virginiamycin M1, protects itself from its own antibiotic by
reducing a critical ketone group to an alcohol at position 16.
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Figure 1 Antibiotic resistance vs. antimicrobial activity mechanism.
Figure 2 Biochemical and genetic aspects of antibiotic resistance mechanisms.
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The most diverse family of resistant enzymes is the group of
transferases. These enzymes inactivate antibiotics (aminogly-
cosides, chloramphenicol, streptogramin, macrolides or rifam-
picin) by chemical substitution (adenylyl, phosphoryl or acetyl
groups are added to the periphery of the antibiotic molecule).
The modiﬁed antibiotics are impaired in their binding to a
target. Chemical strategies include O-acetylation and N-acetyla-
tion (Blanchard, 2004; Schwarz et al., 2004), O-phosphorylation
(Matsuoka and Sasaki, 2004), O-nucleotidylation (Brisson-Noel
et al., 1988), O-ribosylation, O-glycosylation, and thioltransfer. These covalent modiﬁcation strategies all require a
co-substrate such as ATP, acetyl-CoA, NAD+, UDP-glucose,
or glutathione for their activity and consequently these
processes are restricted to the cytoplasm.
3.3. Antibiotic resistance via target modiﬁcation
The second major resistance mechanism is the modiﬁcation of
the antibiotic target site so that the antibiotic is impotent to
bind properly. However, it is possible for mutational changes
to occur in the target that reduce susceptibility to inhibition
while retaining cellular function (Spratt, 1994).
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4.1. Antibiotic resistance via mutations
There is a substantial number of biochemical mechanisms of
antibiotic resistance that are based on mutational events, like
the mutations of the sequences of genes encoding the target
of certain antibiotics (e.g. resistance to rifampicin and ﬂuoro-
quinolones is caused by mutations in the genes encoding the
targets of these molecules, RpoB and DNA-topoisomerases,
respectively) (Ruiz, 2003). The variation in the expression
of antibiotic uptake or of the efﬂux systems may also be
modiﬁed by mutation (e.g. the reduced expression or absence
of the OprD porin of Pseudomonas aeruginosa reduces the
permeability of the cell wall to carbapenems) (Wolter et al.,
2004).
4.2. Antibiotic resistance via horizontal gene transfer
A principal mechanism for the spread of antibiotic resistance
is by horizontal transfer of genetic material. Antibiotic resis-
tance genes may be transferred by different mechanisms of
conjugation, transformation or transduction. Over the last
15 years, b-lactamase enzymes that have an extended spec-
trum of activity (ESBL) against the majority of b-lactams,
including cephalosporins but not carbapenemases, have
evolved. One of these, CTX-M-15, initially found in E. coli
but now found in other members of Enterobacteriaceae and
frequently associated with a speciﬁc lineage, uropathogenic
clone ST131 (Bush and Fisher, 2011; Woodford et al.,
2011), has spread worldwide. It is often located on highly
mobile IncFII plasmids and associated with mobile genetic
element IS26. The risk of infection is particularly high in
individuals in association with prolonged hospitalization,
catheterization, nursing home residency, previous antibiotic
treatment, underlying renal or liver pathology, and travel to
high-risk areas (Nordmann et al., 2011).
5. ESBL deﬁnition and classiﬁcation
There is no consensus of the precise deﬁnition of ESBLs.
ESBLs are a group of enzymes that break down antibiotics
belonging to the penicillin and cephalosporin groups and ren-
der them ineffective. ESBL has generally been deﬁned as trans-
missible b-lactamases that can be inhibited by clavulanic acid,
tazobactam or sulbactam, and which are encoded by genes
that can be exchanged between bacteria. The currently most
common genetic variant of ESBL is CTX-M (Paterson and
Bonomo 2005; Walsh, 2003).
Beta-lactamases are commonly classiﬁed according to two
general schemes: the Ambler molecular classiﬁcation and the
Bush–Jacoby–Medeiros functional classiﬁcation (Bush et al.,
1995; Ambler, 1980). The Ambler scheme classiﬁes b-lactamas-
es into four classes according to the protein homology of
enzymes. Beta-lactamases of class A, C, and D are serine b-lac-
tamase and class B enzymes are metallo-b-lactamases. The
Bush–Jacoby–Medeiros functional scheme is based on func-
tional properties of enzymes, i.e. the substrate and inhibitor
proﬁles.5.1. SHV type
The SHV family of b-lactamases appears to be derived from
Klebsiella spp. The progenitor of the SHV class of enzymes,
SHV-1, is universally found in K. pneumoniae. In many strains
of K. pneumoniae, the gene encoding SHV-1, or its apparent
precursor, LEN-1, resides within the bacterial chromosome
too; it may be that the gene for SHV-1 b-lactamase evolved
as a chromosomal gene in Klebsiella and was later incorpo-
rated into a plasmid which has spread to other enterobacteria
species. SHV-1 confers resistance to broad-spectrum penicillins
such as ampicillin, tigecycline and piperacillin but not to the
oxyimino substituted cephalosporins (Livermore, 1995). The
SHV-1 b-lactamase is responsible for up to 20% of the plas-
mid-mediated ampicillin resistance in K. pneumoniae species
(Tzouvelekis and Bonomo, 1999).
5.2. TEM type
TEM-1, ﬁrst reported from an E. coli isolate in 1965, has sub-
strate and inhibition proﬁles similar to those of SHV-1 (Datta
and Kontomichalou, 1965). TEM-1 is capable of hydrolyzing
penicillins and ﬁrst generation cephalosporins but is unable
to attack the oxyimino cephalosporin. The ﬁrst TEM variant
with increased activity against extended spectrum cephalospo-
rins was TEM-3 (Soughakoff et al., 1988; Sirot et al., 1987).
TEM-2 the ﬁrst derivative of TEM-1, had a single amino acid
substitution from the original b-lactamase (Barthelemy et al.,
1985). This caused a shift in the isoelectric point from a pI
of 5.4–5.6, but it did not change the substrate proﬁle. TEM-
3, originally reported in 1989, was the ﬁrst TEM-type b-lacta-
mase that displayed the ESBL phenotype (Soughakoff et al.,
1988). In retrospect, TEM-3 may not have been the ﬁrst
TEM-type ESBL. Klebsiella oxytoca, harboring a plasmid car-
rying a gene encoding ceftazidime resistance, was ﬁrst isolated
in Liverpool, England, in 1982 (Du Bois et al., 1995). The
responsible b-lactamase was what is now called TEM-12.
Interestingly, the strain came from a neonatal unit which
had been stricken by an outbreak of K. oxytoca producing
TEM-1 (Du Bois et al., 1995). This is a good example of the
emergence of ESBLs as a response to the selective pressure
induced by extended-spectrum cephalosporins.
5.3. CTX type
A new family of b-lactamases that preferentially hydrolyzes
cefotaxime has arisen. It has been found in isolates of Salmo-
nella enterica serovar, Typhimurium, E. coli mainly and some
other species of Enterobacteriaceae (Gazouli et al., 1998;
Knothe et al., 1983). These are not very closely related to
TEM or SHV b-lactamases (Tzouvelekis et al., 2000). In
addition to the rapid hydrolysis of cefotaxime, another unique
feature of these enzymes is that they are better inhibited by the
b-lactamase inhibitor tazobactam than by sulbactam and cla-
vulanate (Bradford et al., 1998; Ma et al., 1998).
CTX-M b-lactamases are found exclusively in the
functional group 2 (Bush and Jacoby, 2010) and thought to
originate from chromosomal ESBL genes found in Kluyvera
spp. (Bush and Jacoby, 2012), an opportunistic pathogen of
the Enterobacteriaceae found in the environment. The ﬁrst
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more than 100 variants have been sequenced (Bonnet, 2004).
Based on their amino acid sequences, they can be divided into
ﬁve groups (CTX-M group 1, 2, 8, 9, and 25) (Bonnet, 2004).
The origin of the CTX-M enzymes is different from that of
TEM and SHV ESBLs. While SHV-ESBLs and TEM-ESBLs
were generated by amino acid substitutions of their parent
enzymes, CTX-M ESBLs were acquired by the horizontal gene
transfer from other bacteria using genetic apparatuses such as
conjugative plasmid or transposon. The gene sequences encod-
ing CTX-M enzymes show a high similarity to those of b-lac-
tamases of Kluyvera species. In addition, the gene sequences
adjacent to the CTX-M genes of Enterobacteriaceae are also
similar to those surrounding the b-lactamase genes on the
chromosomes of Kluyvera species (Olson et al., 2005;
Humeniuk et al., 2002; Poirel et al., 2002).
Kinetic studies have shown that the CTX-M-type b-lacta-
mases hydrolyze cephalothin or cephaloridine better than ben-
zyl penicillin and they preferentially hydrolyze cefotaxime over
ceftazidime (Tzouvelekis et al., 2000; Bradford et al., 1998).
Although there is some hydrolysis of ceftazidime by these
enzymes, it is usually not enough to provide clinical resistance
to organisms in which they reside. It has been suggested that
the serine residue at position 237, which is present in all of
the CTX-M enzymes, plays an important role in the
extended-spectrum activity of the CTX-M-type b-lactamases
(Tzouvelekis et al., 2000). Although it has been shown not to
be essential, the Arg-276 residue lies in a position equivalent
to Arg-244 in TEM- or SHV-type ESBLs, as suggested by
molecular modeling, and may also play a role in the hydrolysis
of oxyimino cephalosporins (Gazouli et al., 1998). Recent crys-
tallographic data for the Toho-1 enzyme suggested that there
was increased ﬂexibility of the interacting b 3 strands and x
loop of this enzyme in comparison to other class A b-lactamas-
es. Furthermore, the lack of hydrogen bonds in the vicinity of
the x loop could account for the extended-spectrum phenotype
(Ibuka et al., 1999).
5.4. OXA type
The OXA-type b-lactamases are so named because of their
oxacillin-hydrolyzing abilities. These b-lactamases are char-
acterized by hydrolysis rates for cloxacillin and oxacillin
greater than 50% as that for benzyl penicillin (Bush et al.,
1995). They predominantly occur in P. aeruginosa
(Weldhagen et al., 2003) but have been detected in many
other Gram-negative bacteria. In fact, the most common
OXA-type b-lactamase, OXA-1 has been found in 1–10%
of E. coli isolates (Livermore, 1995). The OXA-type ESBLs
were originally discovered in P. aeruginosa isolates from a
single hospital in Ankara, Turkey. In France, a novel
derivative of OXA-10 (numbered OXA-28) was found in a
P. aeruginosa isolate (Poirel et al., 2001). A novel ESBL
(OXA-18) and an extended-spectrum derivative of the
narrow spectrum OXA-13 b-lactamase (numbered OXA-19)
have also been discovered in France in P. aeruginosa isolates
(Philippon et al., 1997). The evolution of ESBL OXA-type
b-lactamases from parent enzymes with narrower spectra
has many parallels with the evolution of SHV- and TEM-
type ESBLs. Unfortunately there are very few epidemiologicdata on the geographical spread of OXA-type ESBLs
(Philippon et al., 1997).
5.5. PER type
The PER-type ESBLs share only around 25–27% homology
with known TEM- and SHV-type ESBLs (Bauernfeind et al.,
1996). PER-1 b-lactamase efﬁciently hydrolyzes penicillins
and cephalosporins and is susceptible to clavulanic acid inhibi-
tion. PER-1 was ﬁrst detected in P. aeruginosa (Neuhauser
et al., 2003), and later in S. enterica serovar Typhimurium
and Acinetobacter isolates as well (Vahaboglu et al., 2001).
In Turkey, as many as 46% of nosocomial isolates of Acineto-
bacter spp. and 11% of P. aeruginosa were found to produce
PER-1 (Vahaboglu et al., 1997). PER-2, which shares 86%
homology to PER-1, has been detected in S. enterica serovar
Typhimurium, E. coli, K. pneumoniae, Proteus mirabilis, and
Vibrio cholerae O1 El Tor (Petroni et al., 2002).
5.6. GES type
GES-1 was initially described in a K. pneumoniae isolate from a
neonatal patient just transferred to France from French
Guiana (Poirel et al., 2000). GES-1 has hydrolytic activity
against penicillins and extended-spectrum cephalosporins,
but not against cephamycins or carbapenems, and is inhibited
by b-lactamase inhibitors. These enzymatic properties resem-
ble those of other class A ESBLs; thus, GES-1 was recognized
as a member of ESBLs.
5.7. VEB-1, BES-1, and other ESBL type
Other unusual enzymes having ESBL have also been described
(e.g. BES-1, CME-1, VE-B-1, PER, SFO-1, and GES-1)
(Bradford, 2001). These novel enzymes are found infrequently,
details of these enzymes are reviewed elsewhere (Naas et al.,
2008).
6. Detection
Observation of organisms harboring ESBLs provides clinicians
with helpful information. Treatment of infections caused by
ESBL-producing organisms with extended-spectrum cephalo-
sporins or aztreonam may result in treatment failure even
when the causative organisms appear to be susceptible to these
antimicrobial agents by routine susceptibility testing (Paterson
and Bonomo, 2005; Paterson et al., 2001). Additionally,
patients colonized or infected with ESBL-producing organism
should be placed under contact precautions to avoid hospital
transmission (Siegel et al., 2006). These beneﬁts summon the
detection of ESBL-producing organisms in clinical laborato-
ries. Further, revision of cephalosporin breakpoints has been
achieved by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) and is under way by the
Clinical and Laboratory Standards Institute (CLSI) for better
prediction of clinical outcome by MIC values (Kahlmeter,
2008). It is still controversial whether this revision might allow
clinical laboratories to dispense with ESBL detection (Paterson
and Bonomo, 2005; Kahlmeter, 2008).
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The US Clinical and Laboratory Standards Institute (CLSI)
and the UK Health Protection Agency (HPA) have published
guidelines for ESBL detection in Enterobacteriaceae speciﬁ-
cally for E. coli, Klebsiella spp., and Proteus spp. (CLSI,
2002; HPA, 2008). The HPA guidelines also include other
species, such as Salmonella spp. These guidelines are based
on the principle that most ESBLs hydrolyze third-generation
cephalosporins although they are inhibited by clavulanate,
and recommend initial screening with either 8 mg/L (CLSI)
or 1 mg/L (HPA) of cefpodoxime, 1 mg/L each of cefotaxime,
ceftazidime, ceftriaxone, or aztreonam, followed by conﬁrma-
tory tests (including the E-test ESBL strips) with both
cefotaxime and ceftazidime in combination with clavulanate
at a concentration of 4 lg/mL. Automated systems that use
similar detection principles have proved to be popular in clin-
ical laboratories, especially those in North America and cer-
tain European countries (Spanu et al., 2006). If clinical
laboratories adhere to the published guidelines for detecting
ESBLs, the CLSI and HPA published methods show high
sensitivity of up to 94% and speciﬁcity of 98% for detecting
ESBLs in E. coli, Klebsiella spp. and Proteus spp. (Wiegand
et al., 2007).
6.2. Genotypic detection
The determination of whether a speciﬁc ESBL present in a
clinical isolate is related to TEM and SHV enzymes is a com-
plicated process because point mutations around the active
sites of the TEM and SHV sequences have led to amino acid
changes that increase the spectrum of activity of the parent
enzymes, such as in TEM1, TEM2, and SHV1 (Bradford,
2001). The molecular method commonly used is the PCR
ampliﬁcation of the blaTEM and blaSHV genes with oligonu-
cleotide primers, followed by sequencing. Sequencing is
essential to discriminate between the non-ESBL parent
enzymes (e.g. TEM1, TEM2, or SHV1) and different variants
of TEM or SHV ESBLs (e.g. TEM3, SHV2, etc.) (Bradford,
2001).
The PCR ampliﬁcation of CTX-M-speciﬁc products with-
out sequencing, in an isolate that produces an ESBL, usually
provides sufﬁcient evidence that a blaCTX-M gene is responsible
for this phenotype. This is unlike TEM and SHV types of
ESBLs. Several recent studies have described various
molecular approaches for the rapid screening of ESBL-positive
organisms for the presence of different blaCTX-M genes. This
involved a PCR assay that used four sets of primers to amplify
group speciﬁc CTX-M b-lactamase genes (Pitout et al., 2004),
ampliﬁcation of a universal DNA fragment speciﬁc for most of
the different groups of CTX-M b lactamases (Batchelor et al.,
2005), duplex PCR (Pitout et al., 2007), multiplex PCR
(Woodford et al., 2006), real-time PCR (Birkett et al., 2007),
pyrosequencing (Naas et al., 2007), and reverse-line hybridiza-
tion (Ensor et al., 2007). Molecular techniques undoubtedly
have the potential to play an essential part in the laboratory
setting for the screening, tracking, and monitoring of the
spread of large number of organisms producing CTX-M
enzymes from the community and hospital settings in real
time.7. Epidemiology
The epidemiology of ESBLs is quite complicated. Initially,
there are certain levels to consider: the wider geographical
area, the country, the hospital, the community, and the host
(in most cases a single patient or a healthy carrier). Moreover,
these are bacteria (E. coli is more endemic, and K. pneumoniae
is more epidemic) and their mobile genetic elements, usually
plasmids. Additionally, there are various reservoirs, including
the environment (e.g. soil and water), wild animals, farm ani-
mals, and pets. The ﬁnal component entails transmission from
food and water, and via direct or indirect contact (person to
person) (Carattoli, 2008). The ﬁrst ESBL to be identiﬁed was
found in Germany in 1983, but it was in France in 1985 and
in the United States at the end of the 1980s and the beginning
of the 1990s that the initial nosocomial outbreaks occurred
(Rice et al., 1990). Soon thereafter, it was discovered that
many of the K. pneumoniae strains that caused nosocomial
infections in France in the early 1990s were ESBL producers
(Sirot et al., 1987).
From an international aspect, the use of antibiotics, espe-
cially broad-spectrum agents, is narrow in Sweden (Cars
et al., 2001). Since February 2007, clinical laboratories are
required to report all cases involving ESBL-producing Entero-
bacteriaceae strains to the Swedish Institute for Infectious Dis-
ease Control, and the number of such cases increased by 100%
from 2008 to 2011 (SIIDC, 2012). In recent years, there have
also been larger nosocomial outbreaks of clonally ESBL
strains: one at a neonatal care unit with ESBL-related mortal-
ities, a large outbreak in Uppsala involving K. pneumoniae
with CTX-M-15, and in Kristiansand caused by a multi resis-
tant CTX-M-15-producing E. coli strain (Alsterlund et al.,
2009). According to data from the European Antimicrobial
Resistance Surveillance System (EARSS), 2.6% of E. coli
and 1.7% of K. pneumoniae strains in Sweden were resistant
to third-generation cephalosporins in 2010 (EARSS, 2011).
New TEM and the SHV enzymes are still emerging in Eur-
ope, and distinct epidemic clones have been found, for example
Salmonella isolates with TEM-52 in Spain (Fernandez et al.,
2006) and E. coli and K. pneumoniae isolates with SHV-12 in
Italy (Perilli et al., 2011). Isolates with the CTX-M-9 group
are common in Spain and strains with the CTX-M-3 enzymes
have been described chieﬂy in Eastern Europe, although clones
producing the CTX-M group 1 (including the CTX-M-15 type)
are the most widespread throughout Europe (Coque et al.,
2008a,b; Canton et al., 2008). Today, E. coli and the CTX-
M enzymes are not uncommon in outpatients. Moreover, the
resistance exhibited by K. pneumoniae has reached a higher
level with emergence of carbapenemases such as OXA-48,
which was ﬁrst found in Turkey (Aktas et al., 2008).
Another investigation was conducted at a tertiary hospital
in Nigeria, among the overall ESBL producing isolates, 35%
being community origin and 65% from hospitals. The ESBL
isolates showed high resistance to tetracycline, gentamicin,
peﬂoxacin, ceftriaxone, cefuroxime, ciproﬂoxacin and
Augmentin (Amoxicillin and clavulanic acid combination).
Conjugation studies for Resistance plasmid transfer showed
non-transference of resistance determinants between the ESBL
transconjugants and recipient strains. Correspondingly, the
plasmid curing studies revealed that the acridine orange could
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tance to the antibiotics after the treatment (Ruth et al., 2011).
A study conducted at the National Public health laboratory
(NPHL), Kathmandu, Nepal reported that 31.57% of E. coli
were conﬁrmed as Extended Spectrum b-lactamase producers,
these isolates further exhibited co-resistance to several
antibiotics (Thakur et al., 2013).
In another research conducted at a tertiary hospital in
Mwanza, Tanzania, the overall prevalence of ESBLs in all
Gram-negative bacteria (377 clinical isolates) was 29%. The
ESBL prevalence was 64% in K. pneumoniae but 24% in
E. coli (Mshana et al., 2009). Dramatic ﬁgures were also
obtained in a small study at an orphanage in Mali, where
63% of the adults and 100% of the children were found to
carry ESBL-producing Enterobacteriaceae that showed
extensive co-resistance to other antibiotics (Tande et al.,
2009). Moreover, in Madagascar, Herindrainy et al. (2011)
observed that 10% of non-hospitalized patients carried
ESBLs, in the majority of the cases CTX-M-15, and these
investigators also found that poverty was a signiﬁcant risk fac-
tor for carriage. Fatemeh et al. found that 26.5% of E. coli and
43% of K. pneumonia were ESBL positive in their study con-
ducted at the Imam Reza hospital of Mashhad, IR Iran. They
indicated the high prevalence of ESBL producing Enterobacte-
riaceae family especially in inpatients (Fatemeh et al., 2012).
The overall data on ESBL-producing Enterobacteriaceae in
the countries of the Middle East are extremely worrisome, and
this region might indeed be one of the major epicenters of the
global ESBL pandemic. Investigation conducted in that
country showed that 61% of E. coli produced ESBLs of the
CTX-M-14, CTX-M 15, and CTX-M 27 types, and all of
strains harbored the TEM enzyme (Al-Agamy et al., 2006).
In a study of inpatients in Saudi Arabia in 2008, Tawﬁk and
colleagues found that 26% of K. pneumoniae isolates produced
ESBLs, the majority of which were SHV-12 and TEM-1
enzymes, and 36% were CTX-M-15 (Tawﬁk et al., 2011).
Another investigation conducted in the same country in
2004–2005 showed that 10% of clinical urinary E. coli isolates
from inpatients and 4% of such isolates from outpatients were
ESBL producers (Khanfar et al., 2009). Moubareck and col-
leagues analyzed fecal samples in Lebanon in 2003 and noted
that ESBL carriage differed somewhat between patients
(16%), healthcare workers (3%), and healthy subjects (2%),
and also that there was a predominance of the CTX-M-15
enzyme (83%) (Moubareck et al., 2005). Other researchers in
Lebanon (Khanfar et al., 2009) observed that the proportion
of ESBL-producing isolates was signiﬁcantly larger among
inpatients (15.4%) than in outpatients (4.5%). Moreover, data
collected over three years in Kuwait showed that the levels of
ESBLs were lower in community isolates of K. pneumoniae
(17%) and E. coli (12%) than in the corresponding hospital
isolates (28% and 26%, respectively) (Al Benwan et al., 2010).
Only lately have we begun to understand the extent of the
ecological disaster related to ESBL-producing Enterobacteria-
ceae in parts of Asia and the Indian subcontinent, and the
number of reports of very high frequency of such bacteria in
those regions continues to rise. It is likely that some of the
successful ESBL-producing clones originate from Asia.
Deﬁcient sewage routines (the ‘‘Delhi belly’’) and poor quality
of drinking water, in combination with a lack of control over
prescription and sales of antibiotics, are probably major
factors that have promoted the development of resistance.The United Nations has estimated the population of Asia to
be 4.2 billion in 2012, and hence it is a very challenging task
to try to stop the growing resistance to antibiotic stemming
from this part of the world as exempliﬁed by the rapid spread
of the carbapenemase NDM-1 (Kumarasamy et al., 2010). A
few articles published as early as the end of the 1980s and
the beginning of the 1990s have reported occurrence of the
SHV-2 and Toho-1 (CTX-M-44) enzymes in China and Japan
(Hawkey, 2008). According to the SENTRY surveillance pro-
gram there have been rapid increase in ESBL-producing K.
pneumoniae (up to 60%) and E. coli (13–35%) in different
parts of China, with a predominance of the CTX-M-14 and
CTX-M-3 enzymes (Hawkey, 2008; Hirakata et al., 2005). It
has been found that 66% of third generation cephalosporin
resistant E. coli and K. pneumoniae from three medical centers
in India harbored the CTX-M-15 type of ESBL, which was
also the only CTX-M enzyme found (Ensor et al., 2006), and
an investigation of 10 other centers in that country showed
that rates of ESBL-producing Enterobacteriaceae reached
70% (Mathai et al., 2002). Recently ESBL production was
observed in 48% of E. coli, 44% of K. pneumoniae and 50%
of P. aeruginosa isolates in a tertiary hospital in Patiala,
Punjab (Rupinder et al., 2013). In other recent studies, authors
observed ESBL rates of 46% and 50% in out- and inpatients,
respectively (Sankar et al., 2012), and Nasa and co-workers
detected ESBL production in almost 80% of clinical isolates
(Nasa et al., 2012). Investigations from India and Pakistan
show an alarming and rapid increase in the prevalence of
Enterobacteriaceae with NDM-1 with prevalence rate from
6.9% in a hospital in Varanasi, India, to 18.5% in Rawalpindi,
Pakistan (Perry et al., 2011) and perhaps the spread of these
enzyme could be even more rapid than the spread of the
CTX-M enzymes.
Majda et al. reported that 72% of E. coli and 65.8% of K.
pneumoniae were ESBL producers at the Microbiology labora-
tory of Shalamar Medical College, Lahore. Sensitivity testing
showed a multidrug resistance in ESBL producing E. coli
and K. pneumoniae. Maximum resistance was recorded in
E. coli (ESBL) as cefotaxime (98.9%), Ceftazidime (96.7%)
and Cefuroxime (93.4%) while minimum resistance was seen
with Imipenem (0.8%), fosfomycin (1.2%) and Nitrofurantoin
as well piperacillin/tazobactam (2.2%) each. The ESBL pro-
ducing Klebsiella showed maximum resistance to ceftazidime
(100%), cefotaxime (89%), and Cefuroxime (84%) while min-
imum resistance was seen with imipenem (4%), Nitrofurantoin
and Piperacillin/Tazobactam (8%) (Majda et al., 2013).
In a most recent study Shakti et al. reported 12.11% ESBL
positive among ICU and NICU isolates and 22.47% ESBL
positive from nosocomial isolates. The author further statically
conﬁrmed that ESBL strains were equally distributed in com-
munity or hospital units. Antibiogram of 23 antibiotics
revealed progressive increase in drug resistance against each
antibiotic with the maximum resistant values recorded against
gentamycin: 92% and 79%, oxacillin: 94% and 69%, ceftriax-
one: 85% and 58%, and Norﬂoxacin 97% and 69% resistance,
in nosocomial and community isolates respectively (Shakti
et al., 2014).
Although there are some differences between countries, the
highest prevalence of ESBL-producing K. pneumoniae in the
world is seen primarily in Latin America, data from 33 centers
in Latin America collected over the period 2004–2007 within
the Tigecycline Evaluation and Surveillance Trial (TEST)
Table 1 Epidemiology of ESBL producing organisms.
S. No. ESBL producing organisms Country/City References
1 E. coli, K. pneumoniae Sweden Alsterlund et al. (2009)
2 Salmonella spp. Spain Fernandez et al. (2006)
3 E. coli, K. pneumoniae Italy Perilli et al. (2011)
4 K. pneumoniae Turkey Aktas et al. (2008)
5 Enterobacteriaceae, P. aeruginosa Nigeria Ruth et al. (2011)
6 E. coli Nepal Thakur et al. (2013)
7 E. coli, K. pneumoniae Tanzania Mshana et al. (2009)
8 E. coli, K. pneumoniae Iran Fatemeh et al. (2012)
9 E. coli Middle East Al-Agamy et al. (2006)
10 E. coli Saudi Arabia Tawﬁk et al. (2011)
11 K. pneumoniae Saudi Arabia Khanfar et al. (2009)
12 E. coli, K. pneumoniae Lebanon Moubareck et al. (2005)
13 E. coli, K. pneumoniae Kuwait Moubareck et al. (2005)
14 E. coli, K. pneumoniae China Hawkey (2008) and Hirakata et al. (2005)
15 E. coli, K. pneumoniae India Ensor et al. (2006) and Nasa et al. (2012)
16 E. coli, K. pneumoniae Punjab Rupinder et al. (2013)
17 E. coli Odisha Shakti et al., 2014
18 Enterobacteriaceae Pakistan Perry et al. (2011)
19 E. coli, K. pneumoniae Lahore Majda et al. (2013)
20 E. coli, K. pneumoniae Latin America Rossi et al. (2008)
21 Enterobacteriaceae Canada Pitout et al. (2005)
22 E. coli United States Winokur et al. (2001) and Sanchez et al. (2012)
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20.8% of 932 E. coli isolates (Rossi et al., 2008).
A large variety of different types of SHV have also been
described. One extensive outbreak of Enterobacteriaceae pro-
ducing the CTX-M-14 enzyme occurred in Calgary, Canada
(Pitout et al., 2005). In a large study performed in 2001, it
was demonstrated that about 5.3% of E. coli in the United
States harbored ESBLs (Winokur et al., 2001), and an
investigation conducted in 2009 showed that 9% of E. coli
isolates at a cancer center in Texas were ESBL producers
(Bhusal et al., 2011). Sanchez et al., investigated data obtained
from The Surveillance Network (TSN) concerning in vitro
antimicrobial resistance in US outpatients between 2000 and
2010, and their results showed that resistance to ceftriaxone
rose from 0.2% to 2.3% and resistance to cefuroxime
increased from 1.5% to 5%, but the bacterial isolates in focus
were not tested for ESBLs (Sanchez et al., 2012). The epidemi-
ology of ESBLs producing organism is shown in Table 1.8. Treatment
The carbapenems (imipenem, meropenem, ertapenem, doripe-
nem) are still the ﬁrst choice of treatment for serious infections
with ESBL-producing E. coli and K. pneumoniae. It has been
reported that >98% of the ESBL-producing E. coli, K. pneu-
moniae and P. mirabilis are still susceptible to these drugs
(Perez et al., 2007). But with the emergence of the carbape-
nem-resistant Enterobacteriaceae, the ‘‘magic bullet’’ is actu-
ally difﬁcult to ﬁnd. There are some older drugs which can
be used to treat the ESBL-producing E. coli or K. pneumoniae
infections. Fosfomycin was reported of having admirable
in vitro activity against the ESBL-producing E. coli or
K. pneumoniae. In Hong Kong, most of the ESBL-producing
E. coli isolates were reported to be sensitive to fosfomycin
(Ho et al., 2010). Colistin is another choice which we canconsider for the treatment of these organisms. Although once
considered as quite a toxic antibiotic, it is a last resort that we
can consider at the present moment as there is no new anti
gram negative antibiotics available for the treatment of these
multidrug resistant organisms. Other than ESBL-producing
organisms, actually colistin is used in the treatment of
multidrug resistant P. aeruginosa, carbapenem resistant
A. baumannii. Close monitoring for the development of side
effects can improve the safety margin when prescribing the
drug. Tigecycline is also one of the drugs in the pipeline which
can be considered for treatment (Perez et al., 2007).
9. Conclusion
The incidence of infections caused by beta-lactam-resistant
organisms due to the production of various enzymes has
increased in recent years. Detection of ESBL production is
of paramount importance both in hospital and community
isolates. Infection-control practitioners and clinicians need
the clinical laboratory to rapidly identify and characterize
different types of resistant bacteria. This in turn is required
to minimize the spread of these bacteria and help select appro-
priate antibiotics. This is particularly true for ESBL-producing
bacteria. The epidemiology of ESBL-producing bacteria is
becoming more complex with increasingly blurred boundaries
between hospitals and the community. The acquisition of
efﬁcient mobile elements has accelerated the transfer of
various antibiotic resistance genes. Probably, a ‘‘super bug’’,
resistant to relatively all licensed antibiotics, may rise in the
future. Constant and careful worldwide surveillance for
multidrug-resistant bacteria is urgently warranted.
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